Article
TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis.
Science translational medicine - 2 Jul 2014
Kleinberger Gernot, Yamanishi Yoshinori, Suárez-Calvet Marc, Czirr Eva, Lohmann Ebba, Cuyvers Elise, Struyfs Hanne, Pettkus Nadine, Wenninger-Weinzierl Andrea, Mazaheri Fargol, Tahirovic Sabina, Lleó Alberto, Alcolea Daniel, Fortea Juan, Willem Michael, Lammich Sven, Molinuevo José L, Sánchez-Valle Raquel, Antonell Anna, Ramirez Alfredo, Heneka Michael T, Sleegers Kristel, van der Zee Julie, Martin Jean-Jacques, Engelborghs Sebastiaan, Demirtas-Tatlidede Asli, Zetterberg Henrik, Van Broeckhoven Christine, Gurvit Hakan, Wyss-Coray Tony, Hardy John, Colonna Marco, Haass Christian
Abstract excerpt
Genetic variants in the triggering receptor expressed on myeloid cells 2 (TREM2) have been linked to Nasu-Hakola disease, Alzheimer's disease (AD), Parkinson's disease, amyotrophic lateral sclerosis, frontotemporal dementia (FTD), and FTD-like syndrome without bone involvement. TREM2 is an innate immune receptor preferentially expressed by microglia and is involved in inflammation and phagocytosis. Whether and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
